Arkadios Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Arkadios Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27M	Sell	9,439 -2,521	-21%	-$552K	0.03%	487
2026 Q1	$2.26M	Sell	11,960 -1,577	-12%	-$276K	0.04%	467
2025 Q4	$2.3M	Sell	13,537 -411	-3%	-$63K	0.04%	412
2025 Q3	$1.84M	Buy	13,948 +123	+0.9%	+$14.8K	0.04%	419
2025 Q2	$1.47M	Buy	13,825 +1,115	+9%	+$121K	0.04%	428
2025 Q1	$1.58M	Buy	12,710 +6,899	+119%	+$900K	0.06%	345
2024 Q4	$716K	Buy	+5,811	New	+$685K	0.04%	413
2021 Q4	–	Sell	-25	Closed	-$3K	–	1197
2021 Q3	$3K	Buy	25 +5	+25%	+$755	﹤0.01%	1709
2021 Q2	$3K	Hold	20	–	–	﹤0.01%	1818
2021 Q1	$3K	Hold	20	–	–	﹤0.01%	1470
2020 Q4	$3K	Hold	20	–	–	﹤0.01%	1206
2020 Q3	$3K	Buy	+20	New	+$2.48K	﹤0.01%	907
2020 Q2	–	Sell	-1	Closed	-$100	–	1054
2020 Q1	$100	Buy	+1	New	+$129	﹤0.01%	1145

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Arkadios Wealth Advisors's JAZZ Position: Q2 2026 in Review

Arkadios Wealth Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 21% in Q2 2026, selling an estimated $552K and leaving 9,439 shares worth $2.27M. The position accounts for 0.03% of the portfolio, ranked #487.

Arkadios Wealth Advisors first reported a position in JAZZ in Q1 2020 and has held it in 13 quarters since. The position peaked at $2.3M in Q4 2025. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Arkadios Wealth Advisors held 9,439 shares of Jazz Pharmaceuticals worth $2.27M as of Q2 2026.
Arkadios Wealth Advisors sold 2,521 Jazz Pharmaceuticals shares in Q2 2026, an estimated $552K.
Jazz Pharmaceuticals made up 0.03% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #487 holding.
Arkadios Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q1 2020 and has held it in 13 quarters since.
Arkadios Wealth Advisors's Jazz Pharmaceuticals position peaked at $2.3M in Q4 2025.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.